Physician profile

Thomas Ray Cartwright

Pulmonary Disease · Lebanon, IN

NPI 1740277466

$860.17

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $289.15 2019-2021
Inspire Medical Systems, INC. $117.36 2021
Mylan Specialty L.P. $52.71 2021
Regeneron Healthcare Solutions, INC. $42.75 2021
Allergan, INC. $32.91 2020
Pfizer INC. $32.76 2022
Boehringer Ingelheim Pharmaceuticals, INC. $30.38 2019-2021
Amgen INC. $29.18 2019
Gilead Sciences, INC. $28.67 2021
United Therapeutics Corporation $20.24 2021
Paratek Pharmaceuticals, INC. $19.54 2021
Avanir Pharmaceuticals, INC. $19.53 2019
Takeda Pharmaceuticals U.S.A., INC. $19.23 2022
Resmed Corp $18.70 2020
Astrazeneca Pharmaceuticals LP $15.35 2021
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Teva Pharmaceuticals USA, INC. $14.94 2021
Fisher & Paykel Healthcare INC $13.98 2020
Janssen Biotech, INC. $13.30 2020
Acorda Therapeutics, INC $13.24 2019
Csl Behring $12.95 2019
Jazz Pharmaceuticals INC. $12.06 2019
Genzyme Corporation $11.24 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas Ray Cartwright

$860.17

in general payments reported 2019-2025

Years
2019-2022
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/350951/thomas-ray-cartwright

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.